CVALF
Price
$1.80
Change
+$0.06 (+3.45%)
Updated
Aug 14 closing price
Capitalization
52.43M
SMMT
Price
$26.68
Change
+$0.23 (+0.87%)
Updated
Aug 15, 04:59 PM (EDT)
Capitalization
19.83B
81 days until earnings call
Interact to see
Advertisement

CVALF vs SMMT

Header iconCVALF vs SMMT Comparison
Open Charts CVALF vs SMMTBanner chart's image
Covalon Technologies
Price$1.80
Change+$0.06 (+3.45%)
Volume$900
Capitalization52.43M
Summit Therapeutics
Price$26.68
Change+$0.23 (+0.87%)
Volume$37.24K
Capitalization19.83B
CVALF vs SMMT Comparison Chart in %
Loading...
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CVALF vs. SMMT commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVALF is a Hold and SMMT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (CVALF: $1.91 vs. SMMT: $26.69)
Brand notoriety: CVALF and SMMT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVALF: 10% vs. SMMT: 76%
Market capitalization -- CVALF: $52.43M vs. SMMT: $19.83B
CVALF [@Biotechnology] is valued at $52.43M. SMMT’s [@Biotechnology] market capitalization is $19.83B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVALF’s FA Score shows that 0 FA rating(s) are green whileSMMT’s FA Score has 1 green FA rating(s).

  • CVALF’s FA Score: 0 green, 5 red.
  • SMMT’s FA Score: 1 green, 4 red.
According to our system of comparison, SMMT is a better buy in the long-term than CVALF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVALF’s TA Score shows that 2 TA indicator(s) are bullish while SMMT’s TA Score has 4 bullish TA indicator(s).

  • CVALF’s TA Score: 2 bullish, 7 bearish.
  • SMMT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SMMT is a better buy in the short-term than CVALF.

Price Growth

CVALF (@Biotechnology) experienced а +8.02% price change this week, while SMMT (@Biotechnology) price change was -6.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

SMMT is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SMMT($19.8B) has a higher market cap than CVALF($52.4M). SMMT has higher P/E ratio than CVALF: SMMT (26.36) vs CVALF (17.48). SMMT YTD gains are higher at: 49.566 vs. CVALF (-14.888). CVALF has higher annual earnings (EBITDA): 4.73M vs. SMMT (-235.08M). SMMT has more cash in the bank: 361M vs. CVALF (18M). CVALF has less debt than SMMT: CVALF (609K) vs SMMT (6.45M). CVALF has higher revenues than SMMT: CVALF (33.8M) vs SMMT (0).
CVALFSMMTCVALF / SMMT
Capitalization52.4M19.8B0%
EBITDA4.73M-235.08M-2%
Gain YTD-14.88849.566-30%
P/E Ratio17.4826.3666%
Revenue33.8M0-
Total Cash18M361M5%
Total Debt609K6.45M9%
FUNDAMENTALS RATINGS
CVALF vs SMMT: Fundamental Ratings
CVALF
SMMT
OUTLOOK RATING
1..100
5165
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
96
Overvalued
PROFIT vs RISK RATING
1..100
6238
SMR RATING
1..100
5599
PRICE GROWTH RATING
1..100
8039
P/E GROWTH RATING
1..100
939
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CVALF's Valuation (59) in the null industry is somewhat better than the same rating for SMMT (96) in the Biotechnology industry. This means that CVALF’s stock grew somewhat faster than SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (38) in the Biotechnology industry is in the same range as CVALF (62) in the null industry. This means that SMMT’s stock grew similarly to CVALF’s over the last 12 months.

CVALF's SMR Rating (55) in the null industry is somewhat better than the same rating for SMMT (99) in the Biotechnology industry. This means that CVALF’s stock grew somewhat faster than SMMT’s over the last 12 months.

SMMT's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for CVALF (80) in the null industry. This means that SMMT’s stock grew somewhat faster than CVALF’s over the last 12 months.

SMMT's P/E Growth Rating (9) in the Biotechnology industry is significantly better than the same rating for CVALF (93) in the null industry. This means that SMMT’s stock grew significantly faster than CVALF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVALFSMMT
RSI
ODDS (%)
Bearish Trend 2 days ago
61%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
67%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
60%
Bullish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 22 days ago
66%
Bullish Trend 12 days ago
86%
Declines
ODDS (%)
Bearish Trend 10 days ago
68%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
CVALF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TGONF18.000.10
+0.56%
Tetragon Financial Group
QMOM62.390.03
+0.04%
Alpha Architect US Quantitative Momt ETF
IYC102.72-0.07
-0.07%
iShares US Consumer Discretionary ETF
TMET24.26-0.07
-0.29%
iShares Transition-Enabling Metals ETF
KWT39.32-0.17
-0.43%
iShares® MSCI Kuwait ETF

CVALF and

Correlation & Price change

A.I.dvisor tells us that CVALF and SMMT have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CVALF and SMMT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVALF
1D Price
Change %
CVALF100%
+5.92%
SMMT - CVALF
27%
Poorly correlated
+0.91%
GNFT - CVALF
25%
Poorly correlated
-2.92%
AKBLF - CVALF
21%
Poorly correlated
N/A
TARA - CVALF
21%
Poorly correlated
-5.02%
MBIO - CVALF
20%
Poorly correlated
-0.56%
More

SMMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SMMT
1D Price
Change %
SMMT100%
+0.91%
BCDA - SMMT
70%
Closely correlated
+1.59%
TIL - SMMT
55%
Loosely correlated
-1.43%
BNTX - SMMT
52%
Loosely correlated
+0.73%
RLAY - SMMT
47%
Loosely correlated
+4.42%
FHTX - SMMT
42%
Loosely correlated
-3.21%
More